Quick-Med Technologies, Inc. announced that data on three of its proprietary antimicrobial technologies to be presented at the 2009 Symposium on Advanced Wound Care and the Wound Healing Society meeting. Scientists of Quick-Med will present four abstracts at the prestigious meeting to be held in Dallas, Texas, on April 26-29, 2009 Two abstracts feature key aspects of the NIMBUS Barrier Gauze Dressing, a novel, non-leaching antimicrobial technology that recently received FDA clearance: Antimicrobial Wound Dressings: Mechanisms and Function – A profile of the barrier properties of NIMBUS that substantiates its performance in the presence of wound exudate while permitting safe and rapid healing without risk of bacterial mutation. It is a predicate material ready for incorporation into other application formats. Bacterial Resistance Issues in Wound Care and Wound Dressings – A review of the basic process that leads to the development of bacterial resistance by various microbicidal materials and a summary of the test results demonstrating that NIMBUS does not display this mutation effect. NIMBUS offers improved safety and efficacy. It is unique in that it is a sterile bacterial barrier that prohibits the transfer of microorganisms into the wound because the microbicidal agent is irreversibly bound to the dressing. NIMBUS is non-toxic, long-lasting and not blocked by organics such as blood, urine and perspiration. Product labeling has been allowed that indicates various organisms such as MRSA, VRE, Pseudomonas aeruginosa and Escherichia coli are killed at levels exceeding 99.999%. NIMBUS barrier gauze will be available in June under license from Quick-Med and will be marketed as BIOGUARD by Derma Sciences.